Since the discovery of tankyrase as a positive regulator of Wnt/β-catenin signaling [8], tankyrase has particularly been considered as a promising molecular target for CRC therapy and studies on tankyrase inhibitor development is actively ongoing. The gene discussed is TNKS; the disease is colorectal carcinoma.